Estrella Immunopharma 2/14/2024 Earnings Report

Estrella Immunopharma EPS Results

• Actual EPS: -$0.03
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Estrella Immunopharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Estrella Immunopharma Announcement Details

• Date: 2/14/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Estrella Immunopharma (NASDAQ:ESLA) (NASDAQ: ESLA) is a clinical-stage biotechnology company dedicated to developing next-generation immunotherapies for oncology and regenerative medicine. Leveraging a proprietary cell therapy platform, Estrella focuses on creating allogeneic, off-the-shelf treatments that harness both innate and adaptive immune responses to target a range of solid and hematologic malignancies. The company’s lead candidates are designed to overcome tumor heterogeneity and the suppressive tumor microenvironment.

At the core of Estrella’s approach is an ex vivo expansion and engineering process that generates robust gamma delta T-cell products and personalized dendritic cell vaccines. These product candidates include EST-101, an allogeneic gamma delta T-cell therapy for advanced solid tumors, and EST-201, a dendritic cell-based immunotherapy for hematologic cancers. Preclinical and early-stage clinical data have demonstrated favorable safety profiles and preliminary signs of anti-tumor activity, supporting ongoing trials in multiple cancer indications.

Founded in 2018 and headquartered in Houston, Texas, Estrella Immunopharma extends its reach through collaborations with academic medical centers and contract development organizations in North America, Europe and Asia. The company operates state-of-the-art research and manufacturing facilities, enabling seamless translation from laboratory discovery to clinical manufacturing. Strategic partnerships with leading oncology centers help accelerate patient enrollment and trial execution across diverse geographic regions.

Estrella’s leadership team combines seasoned biotech executives and renowned scientific experts. Chief Executive Officer Dr. Rebecca Sato brings over 20 years of drug development experience, while Chief Scientific Officer Dr. Martin O’Neill oversees translational research and pipeline advancement. Bolstered by a board of directors with deep industry and clinical trial expertise, Estrella Immunopharma continues to advance its immuno-oncology and regenerative medicine programs toward regulatory milestones.